Golden
Prokarium

Prokarium

Prokarium is a biopharmaceutical company focused on developing vaccination and cancer immunotherapy solutions based on synthetic biology.

All edits

Edits on 18 Sep 2019
Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 18 Sep 2019 5:15 am
Edits made to:
Article (+12/-12 characters)

Article

On March 11, 2013 Prokarium and the University of Birmingham's Institute of MicrobiologyMicrobiology and Infection won an award for 'advancing the industrial application of synthetic biology' and received a grant worth £0.4 million. The Technology Strategy Board (TSB), the UK's innovation agency, and the Biotechnology and Biological Sciences Council (BBRSC) issued the grant for the development of Prokarium's Vaxonella oral vaccine delivery platform. 

Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 18 Sep 2019 5:15 am
Edits made to:
Article (+13/-13 characters)

Article

On March 11, 2013 Prokarium and the University of Birmingham's Institute of Microbiology and Infection won an award for 'advancing the industrial application of synthetic biology' and received a grant worth £0.4 million. The Technology Strategy Board (TSB), the UK's innovation agency, and the BiotechnologyBiotechnology and Biological Sciences Council (BBRSC) issued the grant for the development of Prokarium's Vaxonella oral vaccine delivery platform. 

Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 18 Sep 2019 4:53 am
Edits made to:
Article (+9/-9 characters)

Article

In February 2018 , Prokarium completed an investment round, raising $10 million for the clinical development of vaccines against chlamydiachlamydia, C.difficile and enteric fever, in addition to an expansion for the immune-oncology R&D team. This financing round was led by Riyadh Valley Company, followed by Prokarium's original investor Flerie Invest as well as Korea Investment Partners.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 17 Sep 2019 11:40 pm
Edits made to:
Article (+17/-17 characters)

Article

Prokarium's stated vision is that all protein vaccines can be delivered orally. Prokarium is based in Keele and London, UK.The firm has developed a proprietary synthetic biologysynthetic biology platform, Vaxonella, that enables thermostable microbes to be taken orally, to then produce vaccines from inside the body's own immune cells. Vaxonella has 12-week thermostability at 400C. The only other known vaccine to remain stable at this temperature is the meningitis A vaccine MenAfriVac, but only for up to four days.

Edits on 17 Sep 2019
Golden AI
Golden AI edited on 17 Sep 2019 11:11 am
Edits made to:
Infobox (+1 properties)
Dawson Sewell
Dawson Sewell edited on 17 Sep 2019 11:09 am
Edits made to:
Article (+1949 characters)

Article

Funding

Gant I

On July 25, 2016 Prolarium received a grant worth £2 million from the UK and Mexican governments for developing vaccines for Zika, bacterial diarrhoea, and plague. Dr. Ted Fjallman, the CEO of Prokarium, made the following comment regarding the company's $2 million grant:

We’re delighted to be recognised by some of the brightest minds in vaccine research and to receive contracts from both the UK & Mexican Governments.

Grant II

On March 11, 2013 Prokarium and the University of Birmingham's Institute of Microbiology and Infection won an award for 'advancing the industrial application of synthetic biology' and received a grant worth £0.4 million. The Technology Strategy Board (TSB), the UK's innovation agency, and the Biotechnology and Biological Sciences Council (BBRSC) issued the grant for the development of Prokarium's Vaxonella oral vaccine delivery platform. 

Venture funding

On February 26, 2018 Prokarium completed a venture funding round with $10 million in funding from Riyadh Valley Company (lead investor), Flerie Invest, and Korea Investment Partners. The company plans on using the funding to clinically develop their vaccines against Chlamydia, C.difficile and enteric fever (typhoid and paratyphoid), and expand their immuno-oncology research and development team. Dr. Ted Fjallman, the CEO of Prokarium, made the following comment regarding the company's $10 million funding round:

The vaccine industry and the synthetic biology community in the UK are thriving and our team has worked hard to play a central role in both, winning several prestigious grants and government contracts. The new investment by RVC, Flerie and KIP is a clear endorsement of Prokarium’s leadership in developing novel, targeted medicines to prevent serious illnesses. We look forward to generating the clinical data for our current vaccines and working with our investors to find new opportunities to partner our technologies globally.



Edits on 13 Sep 2019
Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 13 Sep 2019 8:09 pm
Edits made to:
Article (+6/-6 characters)

Article

Prokarium's development pipeline also includes a vaccine against plague, being taken into a phase 1 clinical trial under a SBRI contract funded by the UK Department of HealthHealth and Social Care and managed by Innovate UK, paving the way for new biodefence and epidemic preparedness applications.

Edits on 9 Sep 2019
Julius John Villarisco"Approved suggestion from source: https://www.prokarium.com/"
Julius John Villarisco approved a suggestion from Golden's AI on 9 Sep 2019 10:53 pm
Edits made to:
Infobox (+1 properties)
Edits on 9 Sep 2019
Dawson Sewell
Dawson Sewell edited on 9 Sep 2019 1:32 pm
Edits made to:
Infobox (+3 properties)
Edits on 19 Mar 2019
Golden AI
Golden AI edited on 19 Mar 2019 3:13 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 30 Sep 2018
Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 30 Sep 2018 12:27 am
Edits made to:
Article (+11/-11 characters)

Article

Prokarium's development pipeline also includes a vaccine against plague, being taken into a phase 1 clinical trial under a SBRI contract funded by the UK Department of Health and Social Care and managed by Innovate UKInnovate UK, paving the way for new biodefence and epidemic preparedness applications.

Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 30 Sep 2018 12:24 am
Edits made to:
Article (+5/-5 characters)

Article

Prokarium's stated vision is that all protein vaccines can be delivered orally. Prokarium is based in KeeleKeele and London, UK.The firm has developed a proprietary synthetic biology platform, Vaxonella, that enables thermostable microbes to be taken orally, to then produce vaccines from inside the body's own immune cells. Vaxonella has 12-week thermostability at 400C. The only other known vaccine to remain stable at this temperature is the meningitis A vaccine MenAfriVac, but only for up to four days.

Edits on 28 Sep 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 28 Sep 2018 12:49 am
Edits made to:
Article (+6/-6 characters)

Article

Prokarium's stated vision is that all protein vaccines can be delivered orally. Prokarium is based in Keele and LondonLondon, UK.The firm has developed a proprietary synthetic biology platform, Vaxonella, that enables thermostable microbes to be taken orally, to then produce vaccines from inside the body's own immune cells. Vaxonella has 12-week thermostability at 400C. The only other known vaccine to remain stable at this temperature is the meningitis A vaccine MenAfriVac, but only for up to four days.

Carla Faraguna
Carla Faraguna edited on 28 Sep 2018 12:35 am
Edits made to:
Infobox (+2 properties)
Description (+137 characters)
Article (+1175 characters)
Categories (+1 topics)
Related Topics (+2 topics)
Topic thumbnail

Prokarium

Prokarium is a biopharmaceutical company focused on developing vaccination and cancer immunotherapy solutions based on synthetic biology.

Article

Prokarium's stated vision is that all protein vaccines can be delivered orally. Prokarium is based in Keele and London, UK.The firm has developed a proprietary synthetic biology platform, Vaxonella, that enables thermostable microbes to be taken orally, to then produce vaccines from inside the body's own immune cells. Vaxonella has 12-week thermostability at 400C. The only other known vaccine to remain stable at this temperature is the meningitis A vaccine MenAfriVac, but only for up to four days.



In February 2018 , Prokarium completed an investment round, raising $10 million for the clinical development of vaccines against chlamydia, C.difficile and enteric fever, in addition to an expansion for the immune-oncology R&D team. This financing round was led by Riyadh Valley Company, followed by Prokarium's original investor Flerie Invest as well as Korea Investment Partners.

...

Prokarium's development pipeline also includes a vaccine against plague, being taken into a phase 1 clinical trial under a SBRI contract funded by the UK Department of Health and Social Care and managed by Innovate UK, paving the way for new biodefence and epidemic preparedness applications.

Infobox

Categories

Related Topics

Edits on 14 Jun 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 14 Jun 2018 5:24 pm
Edits made to:
Topic thumbnail

 Prokarium

Prokarium is a biopharmaceutical company focused on developing vaccination and cancer immunotherapy solutions based on synthetic biology.

No more activity to show.